secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001662774-24-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients
-----------------------------------------------------------------------------

- Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.
- Cash, equivalents, and short-term investments of $47.8M; runway expected into 2026 through topline results.
- Net loss of $5.5M ($0.13 per share) for Q3 2024; R&D expenses $4.9M, G&A expenses $3.6M.
- Plans to initiate a Phase 2 Duchenne muscular dystrophy study in 2025.
- Identified 11 potential new rare disease indications for EryDex beyond A-T and DMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/0001662774-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/qncx-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001662774-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer